Genetic risk test for prostate cancer (AntePC)

• analyzes of 121 genetic variants associated with prostate cancer;
• individual polygenic risk score for prostate cancer;
• the individual risk of prostate cancer compared to the rest of the male population;
• likelihood to get prostate cancer in 10 years and risk assessment compared to a man with average genetic risk;
• interpretation of the test results with clinical recommendations.
  

• AntePC test is not used to diagnose prostate cancer;
• AntePC test is not validated for use by individuals of non-European descent;
• an elevated risk estimated by the AntePC test does not mean that you will develop prostate cancer during your lifetime. Also, a moderate or lower risk does not mean that the probability of developing the diseases is zero;
• AntePC test does not assess the risk of your family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children;
• AntePC test does not analyze rare pathogenic mutations in genes that significantly increase the risk of prostate cancer, such as BRCA1, BRCA2, ATM, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6 and others;
• the AntePC test is based on the most up-to-date scientific data, which may, however, be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results;
• Different polygenic risk scores predicting risks of the same trait may give different estimates of the individual’s risks due to differences in the genetic variants included in the models and their weights;
• the results of this test should be applied in context with other relevant clinical data. In addition to the possible genetic predisposition, other risk factors also influence the risk of prostate cancer.